This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
1. The subjects have voluntarily signed the informed consent form prior to the start of any procedures related to the study, are able to communicate smoothly with the researcher, understand and are willing to strictly abide by the requirements of this clinical research protocol to complete the study.
2. At the time of signing the informed consent, the subjects are ≥ 18 years old and ≤ 75 years old, male or female.
3. Have atopic dermatitis at screening.
Exclusion Criteria:
1. Hypersensitivity to the study drug or any ingredient in the study drug.
2. Have other active skin disease or skin complications due to other conditions that may affect the evaluation of Atopic Dermatitis (AD).
3. Has malignancy or has a history of malignancy.
4. Have serious concomitant diseases and other conditions that the investigator considers inappropriate to participate in this trial.
5. Females who are pregnant or lactating.
Primary outcome measure(s)
The proportion of subjects whose Eczema Area and Severity Index (EASI) score decreased ≥ 75% compared to the baseline. — Week 16. Eczema Area and Severity Index (EASI) score using the Eczema Area and Severity Index scale.
Trial sites (1)
Facility
City
Region
Status
Dermatology Hospital of Southern Medical University
Guangzhou
Guangdong
Recruiting
More Guangdong Hengrui Pharmaceutical Co., Ltd trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.